James MD - Oncimmune Holdings Chief US
| ONC Stock | 1.14 0.23 16.79% |
Executive
James MD is Chief US of Oncimmune Holdings plc
| Phone | 44 1157 840 500 |
| Web | https://www.oncimmune.com |
Oncimmune Holdings Management Efficiency
The company has return on total asset (ROA) of (0.3023) % which means that it has lost $0.3023 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.6096) %, meaning that it generated substantial loss on money invested by shareholders. Oncimmune Holdings' management efficiency ratios could be used to measure how well Oncimmune Holdings manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Trond Kathenes | Grieg Seafood | 63 | |
| Edil Hernandez | Accesso Technology Group | N/A | |
| Kathleen Mathisen | Grieg Seafood | 54 | |
| Magnus Johannesen | Grieg Seafood | N/A | |
| Jason Jones | Accesso Technology Group | N/A | |
| Julia Mueller | K3 Business Technology | N/A | |
| Alexander OConnell | Fevertree Drinks Plc | 37 | |
| Maurice Veghel | Sligro Food Group | 51 | |
| Bert Vanmoortel | Sligro Food Group | 42 | |
| Michelle Jacques | Molson Coors Beverage | 47 | |
| AnneMarie DAngelo | Molson Coors Beverage | 47 | |
| Atle Sandtorv | Grieg Seafood | 58 | |
| Traci Mangini | Molson Coors Beverage | 55 | |
| Rahul Goyal | Molson Coors Beverage | N/A | |
| Bart Luijten | Sligro Food Group | 57 | |
| de Rooij | Sligro Food Group | N/A | |
| Jack Watson | Bytes Technology | 41 | |
| Charles Gibb | Fevertree Drinks Plc | N/A | |
| Grant Cumming | Grieg Seafood | 54 | |
| Kees Kiestra | Sligro Food Group | 56 | |
| Clare Metcalfe | Bytes Technology | 56 | |
Management Performance
| Return On Equity | -7.61 | |||
| Return On Asset | -0.3 |
Oncimmune Holdings plc Leadership Team
Elected by the shareholders, the Oncimmune Holdings' board of directors comprises two types of representatives: Oncimmune Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncimmune. The board's role is to monitor Oncimmune Holdings' management team and ensure that shareholders' interests are well served. Oncimmune Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncimmune Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA FCA, Exec | ||
| BSc FRCP, Chief Officer | ||
| James MD, Chief US | ||
| Adam Hill, CEO Director | ||
| Shane Smith, VP Oncimmune | ||
| Maarten Brusse, Chief Asia | ||
| Ron Kirschner, General COO | ||
| Cla Rosenfeld, Head Relations | ||
| Petra Budde, Chief Officer | ||
| Martin Hudson, Finance Director | ||
| Matthew Hall, Chief Officer | ||
| Martin Gouldstone, CEO Director | ||
| MD BSc, Chief Officer | ||
| Cameron Barnard, Chief Officer |
Oncimmune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncimmune Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.61 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (1.32) % | |||
| Operating Margin | (1.18) % | |||
| Current Valuation | 5.55 M | |||
| Shares Outstanding | 111.77 M | |||
| Shares Owned By Insiders | 31.54 % | |||
| Shares Owned By Institutions | 35.20 % | |||
| Price To Book | 49.27 X | |||
| Price To Sales | 0.47 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Oncimmune Stock
Oncimmune Holdings financial ratios help investors to determine whether Oncimmune Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncimmune with respect to the benefits of owning Oncimmune Holdings security.